Infants who received only breast milk at birth during hospitalization have lower asthma rates: Study

Infants who were exclusively fed breast milk during their hospitalization at birth were 22% less likely to develop asthma in early childhood, according to research presented during the American Academy of Pediatrics 2024 National Conference & Exhibition in Orlando.

The abstract, “Association Between Hospital Feeding Patterns and Childhood Asthma,” found lower rates of asthma in the infants born at the Cincinnati Children’s Hospital Medical Center who were exclusively fed breast milk even after adjusting for maternal race, insurance, infant sex, and length of hospital stay. Researchers will present their findings during the conference at the Orange County Convention Center from Sept. 27-Oct.

“Although the birth hospitalization lasts only a few days, it sets a critical foundation for establishing breastfeeding, which can influence health outcomes like childhood asthma,” said Laura Placke Ward MD, IBCLC, FAAP, a study author and co-director for the Center for Breastfeeding Medicine at Cincinnati Children’s Hospital Medical Center.

“Our study underscores the importance of hospital practices in supporting exclusive breastfeeding, as these early experiences may impact long-term health,” she said.

While longer duration and exclusive breastfeeding are known to reduce asthma risk, the effect of breastfeeding during the birth hospitalization is less understood, the authors note.

Of the 9,649 children included in the study, 81% received some breast milk and 31% exclusively received breast milk during the birth hospitalization. Five percent had a diagnosis of asthma. Infants who received only breast milk had a lower rate of asthma diagnosis compared to those who did not receive any breast milk or did not receive breast milk exclusively after adjusting for sex, race, and insurance status. Additionally, infants whose first feeding was breast milk also had a lower rate of asthma compared to those whose first feeding was not breast milk.

“This finding highlights the need for greater emphasis on supporting and promoting exclusive breastfeeding during the early days of life,” Dr. Ward said. “By focusing on these crucial first days, we may impact children’s health and potentially reduce the risk of chronic conditions like asthma.”

Reference:

Asthma rates lower in children who received only breast milk at birth hospital, American Academy of Pediatrics, Meeting: American Academy of Pediatrics 2024 National Conference & Exhibition.

Powered by WPeMatico

Conversion from sleeve gastrectomy to Ring augmented Roux-en-Y gastric bypass safe and effective for weight loss: Study

Conversion from sleeve gastrectomy to Ring augmented Roux-en-Y gastric bypass safe and effective for weight loss suggest a study published in the BMC Surgery.

Weight recurrence, suboptimal clinical response and functional disorder (such as reflux) after a Sleeve Gastrectomy (SG) are problems that may require conversional surgery. For reflux, conversion to Roux-en-Y Gastric Bypass (RYGB) is considered effective. Regarding treatment for suboptimal clinical response, the technique of choice remains a subject of debate. This study aims to evaluate the safety and effectiveness of conversion from SG to Ring-augmented RYGB ( RaRYGB). All laparoscopic SG to RaRYGB conversions performed between January 2016 and January 2022 were included. Primary outcome was percentage total weight loss (%TWL) after 1-year follow-up.

Secondary outcomes consisted of cumulative %TWL, complications (with a focus on ring-related complications), and resolution of medical-associated problems.Results: They included 50 patients of whom 44 were female. Mean pre-conversion BMI was 37.6 kg/m2. All patients have reached the 1-year follow-up point, however 10 were lost to follow-up. After 1-year mean TWL was 17.8% while mean cumulative TWL, calculated from primary SG, was 32%. A total of 10 complications occurred in 8 patients within 30 days, 6 of which were ≤ CD3a and 4 ≥ CD3b.

One MiniMizer was removed for complaints of severe dysphagia. Of the 35 medical-associated problems present at screening 5 remained unchanged(14.2%), 15 improved(42.9%) and 15 achieved remission(42.9%). The series of 50 patients undergoing conversion from SG to RaRYGB is adequate and successful regarding additional weight loss 1 year after conversion, cumulative weight loss, complication rate and achievement of improvement or remission of medical-associated problems.

Reference:

van Dam, K.A.M., de Witte, E., Broos, P.P.H.L. et al. Short-term safety and effectiveness of conversion from sleeve gastrectomy to Ring augmented Roux-en-Y gastric bypass. BMC Surg 24, 266 (2024). https://doi.org/10.1186/s12893-024-02552-7

Powered by WPeMatico

New imaging technique accurately detects aggressive kidney cancer, claims study

A new study led by investigators from the UCLA Health Jonsson Comprehensive Cancer Center has demonstrated a new, non-invasive imaging technique can accurately detect clear-cell renal cell carcinoma, the most common form of kidney cancer.

The findings, published in The Lancet Oncology, could greatly reduce the number of unnecessary surgeries and ensure that patients receive the right treatment at the right time, potentially changing how doctors diagnose and treat the disease in the future.

“If kidney cancer is diagnosed late, the chances of survival drop significantly, especially if the cancer has spread,” said Dr. Brian Shuch, director of the Kidney Cancer Program and the Alvin & Carrie Meinhardt Endowed Chair in Kidney Cancer Research at UCLA, and lead author of the study. “But if caught early, over 90% of patients can survive for at least five years. If we are going to survey more tumors, it’s crucial to accurately identify clear-cell renal cell carcinoma early on as they have a greater propensity to grow and spread.”

Kidney cancers, known as renal cell carcinomas, make up 90% of solid kidney tumors. Every year more than 81,000 people in the United States are diagnosed with kidney cancer. Among the many types of these cancers, the most common and deadly is clear-cell renal cell carcinoma, which accounts for 75% of cases and 90% of kidney cancer deaths. Traditional imaging methods like CT or MRI often struggle to differentiate between benign and malignant tumors, leading to either unnecessary surgeries or delayed treatment.

To help improve the detection of clear-cell renal cell carcinoma, the team tested a non-invasive method that uses a monoclonal antibody drug called 89Zr-TLX250, which targets the protein CA9 that is often found in clear-cell renal cell carcinoma.

The phase 3 trial, called ZIRCON, included 332 patients with suspect lesions detected on their kidney from 36 research hospitals from nine different countries with UCLA leading international accrual. The average age of participants was 61 years, with 71% being male and 29% female.

The patients were injected with 89Zr-TLX250, which travels through the body and attaches to the protein CA9 if present in the kidney mass. CA9 is highly expressed in up to 95% of clear cell kidney cancers with minimal expression in normal tissue.

A few days after the injection, patients received a PET-CT scan to detect the radioactive part of the drug, which lights up on the scan wherever the protein is present, allowing doctors to see the cancer more clearly. By looking at the scan, doctors can determine if the kidney mass is likely to be cancerous based on whether or not the 89Zr-TLX250 has attached to the cancer cells.

The new imaging method accurately identified the presence of cancer in most cases while minimizing false positives, demonstrating a high performance with 85.5% sensitivity and 87.0% specificity.

The technique also proved effective even in very small renal masses (less than 2 cm), which are increasingly detected due to more frequent use of abdominal imaging. Additionally, the procedure was shown to be safe, with no significant side effects associated with the use of 89Zr-TLX250.

“The implications of this research are vast,” said Shuch. “If adopted widely, 89Zr-TLX250 PET-CT imaging could become a new standard in kidney cancer diagnostics, like how PET-CT imaging has revolutionized prostate cancer management. It could also aid in the detection of other types of kidney cancers and help monitor patients at high risk of metastasis.”

“Since joining the UCLA Kidney Cancer Program in the late 1990s with UCLA’s Dr. Arie Belldegrun, a main research focus has been on the CA9 protein, a key marker in kidney cancer,” said study co-author Dr. Allan Pantuck, professor of urology and vice chair of academic affairs for UCLA Urology. “Over the years, our group has explored its potential as a diagnostic and prognostic biomarker, a therapeutic target and a tool for molecular imaging. Our work has led to significant advancements, including clinical trials involving the antibody girentuximab and a UCLA-initiated dendritic cell immunotherapy led by Dr. Alexandra Drakaki, an associate professor of medicine and urology at UCLA. It is very gratifying to see how our pioneering research has contributed to the success of the 89Zr-TLX250 clinical trial, which we believe will help reduce unnecessary surgeries and improve treatment outcomes for patients.”

The team will now be looking to see whether 89Zr-TLX250 PET-CT imaging can also identify disseminated or distant disease. A new clinical trial (CANINE) is underway with the aim of detecting metastasis earlier in high-risk patients after nephrectomy. This could help determine proper treatment after surgery. Accurate imaging could intensify planned adjuvant therapy if disease is present or potentially spare patients from unnecessary treatment if disease is absent.

The study was sponsored by Telix Pharmaceuticals.

Reference:

Shuch, Brian et al.,[89Zr]Zr-girentuximab for PET–CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial, The Lancet Oncology, DOI:10.1016/S1470-2045(24)00402-9.

Powered by WPeMatico

Virus-induced inflammation during pregnancy, redefines vertical transmission in COVID-19: Study

A new Cleveland Clinic-led study published in The EMBO Journal shows that mild and asymptomatic SARS-CoV-2 infections can trigger immune responses in a pregnant individual that may cause serious inflammatory responses in the developing fetus. The study’s findings also suggest that vertical transmission of the virus from a pregnant individual to the fetus is more common than previously estimated-and that even without this transmission, a pregnant individual’s immunological response to infection may impact the fetus.

Typically, healthcare providers test for SARS-CoV-2 infection, the virus that causes COVID-19, in a newborn through a nasal swab after birth. For this study, Cleveland Clinic researchers collected samples from the placenta and the fetal compartment (tissues that surround a fetus while still in utero), and then analyzed them for the presence of inflammatory markers and virus. They found higher instances of the virus in those tissues than what could be found in a traditional nasal swab, and even in the absence of a full infection they found small proteins from the virus had passed through the placenta. The researchers hope their study will help ensure pregnant individuals can rapidly and reliably receive evidence-based medical care needed during novel outbreaks and public health crises.

When the COVID-19 pandemic first began, OB/GYN Ruth Farrell, MD, and colleagues at Cleveland Clinic and other major medical centers wanted to determine the best way to prevent and manage the infection in their pregnant patients. Pregnant individuals required different medical considerations during the pandemic compared to their nonpregnant counterparts; Dr. Farrell notes that many of the prevention and treatment approaches used in non-pregnant patients either did not have enough data to use in pregnant patients or were not feasible to perform.

“During the early stages of the pandemic, there were significant delays in determining how best to prevent and treat pregnant patients with SARS-CoV-2 infection,” explains Dr. Farrell, who also serves as the Vice Chair of Research for Cleveland Clinic’s Obstetrics & Gynecology Institute “These delays lead to gaps in our understandings of the COVID pandemic for pregnant persons. These gaps also contribute to disparities that prevented pregnant individuals from accessing the best possible treatment as quickly as possible during the pandemic.”

Dr. Farrell worked with clinical colleagues across the Clinical and Translational Science Collaborative (CTSC) of Northern Ohio to develop methods for examining the impact of SARS-CoV-2 infection on pregnant patients, including researchers from University Hospitals of Cleveland and MetroHealth Medical Center.

She then teamed up with Cleveland Clinic maternal-fetal virologists Jolin (Suan Sin) Foo, PhD and Javier (Weiqiang) Chen, PhD from the Infection Biology Program to determine how the virus impacted the immune systems of both mother and child.

When the standard-of-care COVID-19 test is used to detect the virus in newborns (nasal swabs upon birth) they only detect infections in about 2% of children whose mothers tested positive for the virus during pregnancy. However, when Drs. Chen and Foo looked at tissues that surrounded the newborns when they were still in utero-including the amniotic fluid, chorion and umbilical cord plasma-they detected high levels of the virus in over a quarter (26%) of study participants.

The team also found elevated immune and inflammatory responses affecting the pregnancies of about 66% of study participants. Dr. Foo had previously shown elevated levels of fetal inflammation in pregnant individuals who experience severe SARS-CoV-2 infections during pregnancy, but few had asked whether asymptomatic or mild infections had the same effect. Now that they have their answer, however, the team were faced with even more questions.

“Even though we only saw vertical transmission of the full virus infection a quarter of the time, we saw strong immune and inflammatory responses in over two thirds of the cases,” Dr. Foo says. “It was clear that even when the fetuses were not technically infected, they were still being impacted by their mothers’ viral infection. But we weren’t quite sure how.”

Elevated levels of inflammation during pregnancy, in COVID and other conditions, can have negative impacts on the offspring long after birth. Further research can define how inflammation affects children in the long term.

Dr. Chen noted that the SARS-CoV-2 virus has a protein called ORF8 that physically resembles a human immune protein called immunoglobulin G that passes through the placenta from mother-to-fetus during development. He wondered whether the viral protein could also pass through the placenta’s defenses to cause inflammation in the fetal compartment.

Drs. Foo and Chen, alongside co-first authors Tamiris Azamor, PhD and Débora Familiar-Macedo, PhD (a former and current postdoctoral researcher, respectively, in Dr. Foo’s lab), were able to prove that the virus-made ORF8 did indeed pass through the placenta into the fetus. ORF8 then bound to immune proteins and “turned on” a process called the complementary immune response.

At normal levels, the complement system is a good thing during pregnancy and helps the fetus develop properly, Dr. Familiar-Macedo explains. At higher levels, the complement system can cause dangerous inflammation in a developing fetus. Lab studies supported that this immune response directly led to the elevated levels of inflammation seen in the fetuses of pregnant patients infected with the SARS CoV-2 virus.

“Our findings challenge the currently accepted definition of vertical transmission, or what it means to transmit an infection from mother-to-fetus,” Dr. Chen says. “We have shown that it is indeed possible for only a small part of a virus to slip through and affect a pregnancy.”

Dr. Foo adds that she hopes her team’s findings will serve as guidance for healthcare practitioners, researchers and policymakers alike on further research into vertical transmission and long-term care.

“We’ve shown that the misconception that uninfected babies born from infected mothers are fine, is sometimes just that: a misconception,” she says. “Pregnancy is such a vulnerable nine-month period where any change from the norm can cause long-term impacts on the baby, so we need to work more closely with these individuals to understand their unique healthcare needs during public health crises. It’s the only way to make sure they receive the care they need.” 

Reference:

Tamiris Azamor, Transplacental SARS-CoV-2 protein ORF8 binds to complement C1q to trigger fetal inflammation, The EMBO Journal, https://doi.org/10.1038/s44318-024-00260-9.

Powered by WPeMatico

Study outlines Pitfalls and Promises of Positive End-Expiratory Pressure in Prone Position Surgeries Under GA

During general anesthesia, for specific surgeries performed with patients in the prone position, there is often an increase in airway pressures and a decrease in pulmonary and thoracic compliance, leading to limited chest expansion. This can impact cardiac output and venous return, affecting overall hemodynamic stability. Positive end-expiratory pressure (PEEP) is utilized to alleviate these concerns by enhancing lung recruitment and ventilation and minimizing strain on the lungs. Recent study aimed to evaluate the effects of different positive end-expiratory pressure (PEEP) levels (0 cmH2O, 5 cmH2O, and 10 cmH2O) on respiratory parameters in patients undergoing spine surgery in the prone position under general anesthesia.

The study was a randomized, single-blinded, controlled trial that enrolled 90 patients scheduled for elective spine fixation surgeries. Patients were randomly assigned to one of three groups: Group A (PEEP 0), Group B (PEEP 5), and Group C (PEEP 10). Standardized anesthesia protocols were administered, with ventilation set to pressure-controlled mode at the desired PEEP levels. The key findings were: 1. Arterial oxygenation was significantly higher in Groups B (PEEP 5) and C (PEEP 10) compared to Group A (PEEP 0) at both 30 minutes post-intubation and post-extubation. Specifically, at 30 minutes post-intubation, arterial oxygenation was 142.26 ±24.7 in Group B and 154.9 ±29.88 in Group C, compared to 128.18 ±13.3 in Group A (p=0.002). 2. Mean arterial pressure (MAP) decreased significantly in Groups B and C compared to Group A. 3. Dynamic compliance was improved in Groups B and C compared to Group A. 4. Intraoperative blood loss was notably lower in Group C (329.66 ±93.93) and Group B (421.16 ±104.52) compared to Group A (466.66 ±153.76), and these differences were statistically significant.

Conclusion

These findings suggest that higher levels of PEEP (10 and 5 cmH2O) during prone positioning in spine surgery improve arterial oxygenation, dynamic compliance, and hemodynamic stability while reducing intraoperative blood loss. The study emphasizes the importance of optimizing ventilatory support to enhance patient outcomes during prone-position surgeries. Proper titration of PEEP levels is crucial to balance the benefits of improved respiratory function against potential hemodynamic effects.

Key Points

1. Arterial oxygenation was significantly higher in the groups with PEEP of 5 cmH2O (Group B) and 10 cmH2O (Group C) compared to the group with 0 cmH2O PEEP (Group A), both at 30 minutes post-intubation and post-extubation.

2. Mean arterial pressure (MAP) decreased significantly in the groups with PEEP of 5 cmH2O (Group B) and 10 cmH2O (Group C) compared to the group with 0 cmH2O PEEP (Group A).

3. Dynamic compliance was improved in the groups with PEEP of 5 cmH2O (Group B) and 10 cmH2O (Group C) compared to the group with 0 cmH2O PEEP (Group A).

4. Intraoperative blood loss was notably lower in the group with PEEP of 10 cmH2O (Group C) and the group with PEEP of 5 cmH2O (Group B) compared to the group with 0 cmH2O PEEP (Group A), and these differences were statistically significant.

5. The findings suggest that higher levels of PEEP (10 and 5 cmH2O) during prone positioning in spine surgery improve arterial oxygenation, dynamic compliance, and hemodynamic stability while reducing intraoperative blood loss.

6. The study emphasizes the importance of optimizing ventilatory support to enhance patient outcomes during prone-position surgeries, and proper titration of PEEP levels is crucial to balance the benefits of improved respiratory function against potential hemodynamic effects.

Reference –

Shanmugam Y, Venkatraman R, KY A (September 05, 2024) A Comparison of the Effects of Different Positive End-Expiratory Pressure Levels on Respiratory Parameters During Prone Positioning Under General Anaesthesia: A Randomized Controlled Trial. Cureus 16(9): e68693. DOI 10.7759/cureus.68693

Powered by WPeMatico

Antipsychotics fail to improve cognitive deficit in schizophrenia spectrum disorders: JAMA

A new study published in the Journal of American Medical Association showed that in individuals with schizophrenia spectrum disorders (SSD), not one antipsychotic was linked to superior cognitive results than a placebo. A significant portion of the symptoms of schizophrenia spectrum disorders include cognitive abnormalities, which also significantly increase the burden of the disease. Antipsychotic medications may have varying impacts on cognition because of their distinct receptor-binding characteristics, but they are not cognitive enhancers.

To ascertain if antipsychotic usage is connected with cognitive function in SSDs at all, no prior network meta-analysis compared antipsychotics to placebo. In order to rule out the relationship between therapy with different antipsychotics and cognition in patients with SSDs, Lena Feber and her team carried out this investigation. Through June 25, 2023, this research gathered information from 68 studies published between 1958 and 2022 that were part of the Cochrane Schizophrenia Trials Register. Blinded and unblinded randomized clinical studies that lasted at least 3 weeks and evaluated antipsychotics or antipsychotics vs placebo were included in the review.

Over half of the studies in the study had an overall high risk of bias, and 10 of the trials were open label. In accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses–Network Meta-analysis reporting guideline, a systematic review and random-effects frequentist network meta-analysis were conducted. The change in the total cognitive score of each study was the main result. Functioning, quality of life, and cognitive domains were secondary objectives.

First-generation dopamine antagonists, like fluphenazine and haloperidol, as well as clozapine, which has anticholinergic effects, ranked poorly in this systematic review and pairwise network meta-analysis, which included 68 studies with a total of 9525 participants. Furthermore, no particular antipsychotic was linked to a definite improvement over a placebo, and cognitive function was measured in a very varied and sometimes incomplete manner.

Despite the paucity of available data, the evidence examined in this study indicates that when cognitive problems are a concern, clozapine and first-generation dopamine antagonists should be avoided. Cognitive medicines are not antipsychotics. Rather than cognitive deficiencies in the traditional sense, the overall slight improvement in results over a placebo might be explained by less disorganized thought patterns linked to less pleasant feelings.

Source:

Feber, L., Peter, N. L., Chiocchia, V., Schneider-Thoma, J., Siafis, S., Bighelli, I., Hansen, W.-P., Lin, X., Prates-Baldez, D., Salanti, G., Keefe, R. S. E., Engel, R. R., & Leucht, S. (2024). Antipsychotic Drugs and Cognitive Function. In JAMA Psychiatry. American Medical Association (AMA). https://doi.org/10.1001/jamapsychiatry.2024.2890

Powered by WPeMatico

Long-term antiviral use key to ocular shingles treatment

Taking an antiviral medication for a year may prevent vision damage associated with shingles that affects the eye, according to new research led by faculty from the Perelman School of Medicine at the University of Pennsylvania and the NYU Grossman School of Medicine at NYU Langone Health.

“Up until now, there has been no proven long-term treatment for new, worsening, or repeated episodes of this disease, so the results of this study provide convincing evidence for using long-term, low-dose antiviral treatment,” said Bennie Jeng, MD, chair of Ophthalmology at the Perelman School of Medicine at the University of Pennsylvania and the director of the Scheie Eye Institute at Penn Medicine, who co-chaired the study.

Ocular shingles begins in the nerve connecting the brain to the eye and is present in almost 100,000 of the million people who develop shingles each year in the United States. This is called herpes zoster ophthalmicus (HZO) and can result in keratitis (inflammation of the cornea), iritis (inflammation of the iris), and inflammation in other parts of the eye. Roughly 30,000 of HZO cases result in patients’ vision declining to 20/60 or worse, meaning that if a typically-sighted person could see an object clearly at 60 feet, these patients would have to move up to at least 20 feet to see it. Beyond that, approximately 10,000 patients who develop HZO experience legal blindness, meaning their vision is reduced to 20/200 or worse.

For patients who had recurrences or new findings of HZO, there was never a clear course of treatment to reliably prevent complications such as vision loss.

Elisabeth J. Cohen, MD, a professor of ophthalmology at NYU Grossman School of Medicine, designed the study, after she was, herself, affected by shingles-related vision loss years ago. The study examined the long-term use of the existing antiviral treatment valacyclovir, which is already used to initially treat any case of shingles, albeit only for seven to 10 days. The researchers showed that using valacyclovir for a year can decrease the risk of new or worsening eye disease by 26 percent at 18 months after initiating treatment. Patients treated with valacyclovir also were 30 percent less likely than those not receiving the treatment to have multiple HZO flare-ups at a year or a year-and-a-half later.

“We hope that our work creates a relatively simple path toward preventing vision changes that can be life-altering,” said Jeng. “With this drug already being part of the regular clinical treatment for shingles, we don’t envision significant barriers to making this a standard of treatment.”

The research was presented at both the Cornea and Eye Banking Forum (Oct. 18) and the American Academy of Ophthalmology’s annual meeting (Oct. 19). It resulted from the Zoster Eye Disease Study (ZEDS), an eight-year-long study conducted at 95 medical centers across the United States, Canada, and New Zealand. Cohen led the study with Jeng serving as co-chair.

ZEDS ran from November 2017 until January 2023, enrolling more than 500 participants who had shingles affecting their eyes. Approximately half received daily doses of valacyclovir for a year, with the others receiving a placebo. The ZEDS study also found that this same treatment reduced a chronic nerve pain syndrome that can accompany shingles.

“While our evidence in support of a new treatment regimen is vital, prevention is even more effective than any treatment,” Cohen said. “The incidences of this are going up in persons in their 50s, and just 12 percent of that population has received the highly effective zoster vaccine. It has been recommended since 2018 for all adults age 50 and older, and, since 2022, for immunocompromised adults age 19 and older.”

Moving forward, Jeng said the ZEDS team is looking into whether the extended antiviral treatment is especially effective in reducing glaucoma, scleritis (inflammation affecting the outer eye), and other complications. Additionally, they hope to see what impact vaccination against shingles had on the patients in the study, and whether the shingles vaccine affected COVID-19 diagnosis and severity among participants.

Powered by WPeMatico

Routine blood test can predict pre-eclampsia among women in labour, suggests study

A simple blood test could help doctors identify women in labor who are at risk for preeclampsia-a leading cause of maternal death-and take precautions to prevent it, according to research presented at the ANESTHESIOLOGY® 2024 annual meeting.

Between 5% and 10% of pregnant women develop preeclampsia (sudden high blood pressure and protein in the urine), according to the Centers for Disease Control and Prevention (CDC). Black women are 60% more likely to develop preeclampsia than white women, and more likely to die or have serious outcomes such as kidney damage, the CDC notes. While preeclampsia can develop as early as the 20th week of pregnancy, the study focused on identifying women who were at risk for preeclampsia when they were admitted to the hospital in labor.

Researchers have determined doctors can predict a woman’s risk of developing preeclampsia by calculating the ratio of two blood proteins-fibrinogen and albumin-measured in routine blood tests done when women in labor enter the hospital. Fibrinogen is involved in blood clotting and inflammation, while albumin helps maintain fluid balance and carries hormones, vitamins and enzymes throughout the body. Both can be disrupted with preeclampsia-fibrinogen may be elevated, albumin may be reduced, or both can occur.

There is no universally established normal value for this fibrinogen-to-albumin ratio (FAR), which can range from 0.05 to 1 or higher. Higher FAR values are often associated with increased inflammation, infection or serious health conditions, and the higher the FAR, the greater the concern. This trend has been consistently seen when FAR is used to evaluate other inflammatory conditions, such as rheumatoid arthritis, cardiovascular diseases and inflammatory bowel disease.

In the study, researchers analyzed the records of 2,629 women who gave birth between 2018 and 2024, 1,819 who did not have preeclampsia, 584 who had preeclampsia with mild features or symptoms (including blood pressure of 140/90 mm Hg or higher, but no significant signs of organ damage), and 226 who had preeclampsia with severe features or symptoms (including blood pressure of 160/110 mm Hg or higher and signs of organ damage, including severe headaches, high liver enzymes, visual disturbances, low platelet count or kidney impairment). The researchers determined those who had a higher FAR were more likely to develop preeclampsia than those with a lower FAR. They found that the predicted likelihood of developing any degree of preeclampsia was 24% for patients with a FAR of at least 0.1 on admission to the hospital, and it rose to more than 41% when that value was above 0.3.

If a woman in labor is found to be at increased risk for preeclampsia based on the FAR and other clinical indicators-such as being older than 35 or having chronic high blood pressure or obesity-obstetricians and anesthesiologists can take extra precautions to reduce the risk and ensure the patient’s blood pressure and fluid levels remain stable and controlled. For example, they can order more frequent blood pressure checks or lab tests. If the FAR indicates a woman is at risk for preeclampsia with severe symptoms, an epidural for pain management can be placed early before it becomes too risky.

“While FAR has been associated with other inflammatory conditions, its specific application to preeclampsia and preeclampsia with severe symptoms has not been reported in a group this large and racially diverse,” said Lucy Shang, B.A., lead author of the study and a medical student at the Icahn School of Medicine at Mount Sinai, New York. “Our study shows that FAR can be a predictive tool that gives anesthesiologists and obstetricians a new method for assessing a laboring mom’s risk of developing preeclampsia when they are admitted to the hospital.”

She noted that while this ratio should be assessed for all pregnant women, calculating the FAR is especially important for women who are at higher risk for preeclampsia, such as Black women and those with high blood pressure and obesity. “Additional research is needed to determine the exact range of the FAR that would be considered concerning and would be helpful to incorporate into routine prenatal care as a predictive tool for early identification of preeclampsia,” she said.

Reference:

Routine blood test can identify laboring women at risk for preeclampsia, prompt interventions to protect mom and baby, American Society of Anesthesiologists, Meeting: Anesthesiology 2024.

Powered by WPeMatico

Single-dose premedication of oral diclofenac potassium or prednisolone attenuates immediate postendodontic pain, suggests study

Single-dose premedication of oral diclofenac potassium or prednisolone attenuates immediate postendodontic pain, suggests study published in the Journal of Endodontics.

This prospective, randomized, double-blind clinical trial investigated the impact of diclofenac potassium, prednisolone, and placebo as oral premedication on postendodontic pain and pulpal interleukin (IL)-8 expression in patients with irreversible pulpitis. Thirty-six patients undergoing conventional endodontic treatment were assigned into one of 3 groups (n = 12). Pulpal blood samples were taken after access cavity preparation and stored until they were analyzed using enzyme-linked immunosorbent asssay for quantification of IL-8. Postendodontic pain was scored using the visual analogue scale. Outcome data were statistically analyzed using one-way analysis of variance, Kruskal-Wallis, Friedman’s, Dunn’s, Chi-square, and Fisher’s exact tests and Spearman’s correlation coefficient. The significance level (α) was set at 0.05. Results: Apart from preoperative pain scores, all groups had similar baseline characteristics (P > .05). Immediate postendodontic pain scores had a significant difference between all groups (P < .05) where placebo group showed the highest score. There was no significant difference between all groups at 6 and 12 hours postoperatively (P > .05). Furthermore, there was no significant difference in the incidence of postendodontic pain and in mean IL-8 levels between the 3 groups (P > .05). The only impact the premedications had was on the immediate postendodontic pain intensity, and they had no influence on the later time points, incidence of postendodontic pain or pulpal IL-8 levels.

Reference:

Soliman AA, Ezzat KM, Shaker OG, Abouelenien SS. Influence of Diclofenac Potassium versus Prednisolone on Postendodontic Pain and Pulpal Interleukin-8 Expression in Symptomatic Irreversible Pulpitis Cases: A Randomized Placebo-controlled Trial. J Endod. 2024 Sep;50(9):1213-1220. doi: 10.1016/j.joen.2024.05.019. Epub 2024 Jun 24. PMID: 38925367.

Keywords:

Single-dose, premedication, oral, diclofenac, potassium, prednisolone, attenuates, immediate, postendodontic pain, suggests, study, Journal of Endodontics, Cytokine expression, inflammatory markers, interleukin-8, irreversible pulpitis, Soliman AA, Ezzat KM, Shaker OG, Abouelenien SS

Powered by WPeMatico

Janus kinase inhibitors effective for pain reduction among Rheumatoid Arthritis patients: Study

A recent cohort study revealed that Janus kinase inhibitors (JAKis) are better at providing pain relief than TNF inhibitors (TNFis) at both 3 and 12 months, in rheumatoid arthritis (RA) patients previously treated with multiple biologic disease-modifying anti-rheumatic drugs (bDMARDs). The study findings were published in the journal Arthritis & Rheumatology.

Pain is the key patient-centered concern in Rheumatoid arthritis. Assessment tools for pain include pain measures without any significant emphasis on the pain thus underscoring the gap in the direct pain assessment without any impact on the quality of life. Hence, researchers conducted a study to compare the effectiveness of Janus kinase inhibitors (JAKis) and biologic disease-modifying anti-rheumatic drugs (bDMARDs) in reducing pain among patients with rheumatoid arthritis (RA).

A retrospective analysis was carried out by obtaining data from several Swedish national registers enabling a comprehensive review of treatment outcomes. The analysis included RA patients who were under treatment with various drugs like either a JAKi (n=1,827), TNF inhibitor (TNFi, n=6,422), IL-6 inhibitor (n=887), abatacept (n=1,102), or rituximab (n=1,149) between 2017 and 2019. A visual analogue scale (VAS) was used to measure pain level from 0 to 100 mm, with lower values indicating less pain. Pain was also assessed at baseline, 3 months, and at the end of the treatment. 

The two outcomes of measurement are change in pain from baseline to 3 months and the proportion of patients who achieved and maintained low pain (VAS pain score <20 mm) at 12 months while continuing on their initial treatment. To account for patient characteristics, such as demographics, comorbidities, concurrent medications, and prior treatments, multivariable linear regression models were employed for a more accurate comparison of pain relief between JAKis and various bDMARDs, including TNFis and non-TNFi agents.

Results:

  • A greater reduction in pain at the 3-month mark was experienced by JAKi treated patients than TNFi therapy.
  • Specifically, the adjusted mean decrease in pain for JAKi users was 4.0 mm greater than for TNFi users (95% confidence interval [CI]: 1.6–6.3).
  • Similar trends were seen when comparing JAKis to non-TNFi bDMARDs, suggesting that JAKis may offer superior short-term pain relief across a broad range of biologic therapies.
  • A higher proportion of patients treated with JAKis maintained low pain levels compared to those on TNFis at 12 months.
  • This difference was particularly significant in patients who had previously been treated with two or more bDMARDs, a subgroup often more challenging to treat due to their history of inadequate response to multiple therapies.
  • In this group, JAKi treatment was associated with an adjusted increase of 5.3 percentage points in the likelihood of achieving low pain (95% CI: 1.0–9.6), highlighting the potential advantage of JAKis in more refractory cases of RA.
  • When comparing JAKis to non-TNFi bDMARDs (such as IL-6 inhibitors, abatacept, and rituximab), the pain reduction outcomes at 12 months were similar.
  • This suggests that while JAKis may be slightly more effective in reducing pain in the short term compared to TNFis, their long-term effectiveness in controlling pain is at least comparable to that of non-TNFi bDMARDs.

Thus, the study concluded that JAK inhibitors provide slightly better pain relief at both 3 and 12 months compared to TNF inhibitors, especially in patients who have previously been treated with multiple bDMARDs. Additionally, JAKis were found to be at least as effective as non-TNFi bDMARDs in terms of long-term pain reduction. These findings suggest that JAK inhibitors may be a valuable option for RA patients, particularly those who have experienced suboptimal responses to other bDMARDs.

Further reading: Eberhard, Anna et al. “Effectiveness of janus kinase inhibitors compared with biologic disease modifying anti-rheumatic drugs on pain reduction in rheumatoid arthritis: Results from a nationwide Swedish cohort study.” Arthritis & rheumatology (Hoboken, N.J.), 10.1002/art.43014. 22 Sep. 2024, doi:10.1002/art.43014

Powered by WPeMatico